At a glance
ClinicalIndex Comparison RecordN/ACompleted· 147 enrolled
Drug / intervention
Silverlon® +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Outcomes Between the Use of Silverlon® Dressing and AQUACEL® AG Dressing Post Cardiac Device Implant
In Brief
A clinical study evaluating Silverlon® and AQUACEL® AG for Infections and Wounds and Injuries. Completed, enrolled 147 participants across 1 site.
Detailed Summary
The purpose of this study is to learn how effective each of the two dressings, Silverlon® and AQUACEL® AG, are in preventing post cardiac implantable electronic devices (CIED) procedure wound infections.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Wounds and Injuries
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartJun 2016
Primary CompletionDec 2017
TodayJul 2026
First PostedMay 24, 2016
Enrollment StartJun 1, 2016
Primary CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.1 years ago
Interventions
Silverlon®device
Silverlon wound dressings
AQUACEL® AGdevice
AQUACEL® AG wound dressings